Witt, Kristina
Evans-Axelsson, Susan
Lundqvist, Andreas
Johansson, Martin
Bjartell, Anders
Hellsten, Rebecka http://orcid.org/0000-0002-3735-5636
Funding for this research was provided by:
The Swedish Research Council
The Swedish Cancer Society (#CAN 2018/451, #CAN 2018/522)
The Cancer Foundation at Skåne University Hospital Malmö
The Governmental Funding (ALF) through The Faculty of Medicine
The Prostate Cancer Patient Association in Sweden
The Cancer Research Foundations of Radiumhemmet (#181183)
VINNOVA
Lund University
Article History
Received: 7 October 2020
Accepted: 13 March 2021
First Online: 31 March 2021
Compliance with ethical standards
:
: Rebecka Hellsten owns shares in Glactone Pharma AB. Ander Bjartell is a board member of and owns shares in Glactone Pharma AB. Martin Johansson received consultancy fees from and owns shares in Glactone Pharma AB. The compound GPB730 was provided by Glactone Pharma Development AB.
: All mouse experimental procedures were approved by the Regional Ethics Committee for Animal Research at Lund University, Sweden (permit number M134-14).